Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enterogermina versus metronidazole for eradication of small intestinal bacterial overgrowth in adults with irritable bowel syndrome
2005-004934-42Phase 4Completed
- Sponsor
- Sanofi
- Start
- Jun 2006
- Modality
- Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in blind loop syndrome (BLS) and irritable bowel syndrome (IBS) comparing Enterogermina arm with Metronidazole arm (2 arms). Primary endpoint: Eradication rate of small intestinal bacterial overgrowth. Started Jun 2006; status: completed.
02
Drugs
bacillus clausiimetronidazole
03
Conditions
blind loop syndrome (BLS)irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on 2005-004934-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004934-42.